Nalmefene in the treatment of pathological gambling: Multicentre, double-blind, placebo-controlled study

Jon E. Grant, Brian L. Odlaug, Marc N. Potenza, Eric Hollander, Suck Won Kim

Research output: Contribution to journalArticle

74 Scopus citations

Abstract

Pathological gambling is a disabling disorder experienced by about 1% of adults. We randomised 233 participants (41.6% women) 1:1:1 to nalmefene (20 or 40 mg) or placebo. In analyses performed using an intention-to-treat (ITT) population, nalmefene failed to show statistically significant differences from placebo on primary and secondary outcomes. Post hoc analyses of only participants who received a full titration of the medication for at least 1 week demonstrated that nalmefene 40 mg/day resulted in significantly greater reductions on the primary outcome measure. These findings suggest that medication dosing may be an important consideration in achieving symptom control.

Original languageEnglish (US)
Pages (from-to)330-331
Number of pages2
JournalBritish Journal of Psychiatry
Volume197
Issue number4
DOIs
StatePublished - Oct 1 2010

ASJC Scopus subject areas

  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Nalmefene in the treatment of pathological gambling: Multicentre, double-blind, placebo-controlled study'. Together they form a unique fingerprint.

  • Cite this